Auto-reactions, autoimmunity and psoriatic arthritis

Autoimmunity Reviews

Volumn 14, Issue 12, 2015, Pages 1142-1146

  Chimenti, Maria Sole ^a   Triggianese, Paola ^a   Nuccetelli, Marzia ^a   Terracciano, Chiara ^a   Crisanti, Anna ^a   Guarino, Maria Domenica ^a   Bernardini, Sergio ^a   Perricone, Roberto ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Anti carbamylated protein antibodies; Auto reactions; Autoimmunity; Psoriatic arthritis

Indexed keywords

ANTI CARBAMYLATED PROTEIN ANTIBODY; ANTI CITRULLINE ANTIBODY; AUTOANTIBODY; UNCLASSIFIED DRUG; AUTOANTIGEN; CARBAMOYL PHOSPHATE; CITRULLINE;

ADULT; ANTIBODY DETECTION; AUTOIMMUNITY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; HELPER CELL; HUMAN; MAJOR CLINICAL STUDY; MALE; PLASMA CELL; PSORIATIC ARTHRITIS; REVIEW; SENSITIVITY AND SPECIFICITY; ANIMAL; IMMUNOLOGY;

ANIMALS; ARTHRITIS, PSORIATIC; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNITY; CARBAMYL PHOSPHATE; CITRULLINE; HUMANS;

EID: 84945493101     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2015.08.003     Document Type: Review

References (42)

1. Chimenti M.S., Ballanti E., Perricone C., Cipriani P., Giacomelli R., Perricone R. Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways. Autoimmun Rev 2013, 12:599-606.
2. Lubrano E., Cantini F., Costanzo A., Girolomoni G., Prignano F., Olivieri I., et al. Measuring psoriatic disease in clinical practice. An expert opinion position paper. Autoimmun Rev 2015, 14:864-874.
3. Taylor W., Gladman D., Helliwell P., Marchesoni A., Mease P., Mielants H., et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006, 54:2665-2673.
4. FitzGerald O., Haroon M., Giles J.T., Winchester R. Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype. Arthritis Res Ther 2015, 17:115.
5. Kane D., Stafford L., Bresnihan B., FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) 2003, 42:1460-1468.
6. McGonagle D., Marzo-Ortega H., O'Connor P., Gibbon W., Hawkey P., Henshaw K., et al. Histological assessment of the early enthesitis lesion in spondyloarthropathy. Ann Rheum Dis 2002, 61:534-537.
7. Conigliaro P., Triggianese P., Perricone C., Chimenti M.S., Di Muzio G., Ballanti E., et al. Restoration of peripheral blood natural killer and B cell levels in patients affected by rheumatoid and psoriatic arthritis during etanercept treatment. Clin Exp Immunol 2014, 177:234-243.
8. van Kuijk A.W., Tak P.P. Synovitis in psoriatic arthritis: immunohistochemistry, comparisons with rheumatoid arthritis, and effects of therapy. Curr Rheumatol Rep 2011, 13:353-359.
9. Sakkas L.I., Bogdanos D.P., Katsiari C., Platsoucas C.D. Anti-citrullinated peptides as autoantigens in rheumatoid arthritis-relevance to treatment. Autoimmun Rev 2014, 13:1114-1120.
10. Versini M., Jeandel P.Y., Rosenthal E., Shoenfeld Y. Obesity in autoimmune diseases: not a passive bystander. Autoimmun Rev 2014, 13:981-1000.
11. Grant C.R., Liberal R., Mieli-Vergani G., Vergani D., Longhi M.S. Regulatory T-cells in autoimmune diseases: challenges, controversies and-yet-unanswered questions. Autoimmun Rev 2015, 14:105-116.
12. Crow M.K. Type I interferon in organ-targeted autoimmune and inflammatory diseases. Arthritis Res Ther 2010, 12(Suppl. 1):S5.
13. Ambrosi A., Espinosa A., Wahren-Herlenius M. IL-17: a new actor in IFN-driven systemic autoimmune diseases. Eur J Immunol 2012, 42:2274-2284.
14. Axtell R.C., de Jong B.A., Boniface K., van der Voort L.F., Bhat R., De Sarno P., et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010, 16:406-412.
15. Frey S., Derer A., Messbacher M.E., Baeten D.L., Bugatti S., Montecucco C., et al. The novel cytokine interleukin-36α is expressed in psoriatic and rheumatoid arthritis synovium. Ann Rheum Dis 2013, 1(72):1569-1574.
16. Fitzgerald O., Winchester R. Psoriatic arthritis: from pathogenesis to therapy. Arthritis Res Ther 2009, 11:214.
17. Curran S.A., FitzGerald O.M., Costello P.J., Selby J.M., Kane D.J., Bresnihan B., et al. Nucleotide sequencing of psoriatic arthritis tissue before and during methotrexate administration reveals a complex inflammatory T cell infiltrate with very few clones exhibiting features that suggest they drive the inflammatory process by recognizing autoantigens. J Immunol 2004, 172:1935-1944.
18. Lande R., Botti E., Jandus C., Dojcinovic D., Fanelli G., Conrad C., et al. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun 2014, 5:5621.
19. Tassiulas I., Duncan S.R., Centola M., Theofilopoulos A.N., Boumpas D.T. Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis. Hum Immunol 1999, 60:479-491.
20. Snowden J.A., Kearney P., Kearney A., Cooley H.M., Grigg A., Jacobs P., et al. Long-term outcome of autoimmune disease following allogeneic bone marrow transplantation. Arthritis Rheum 1998, 41:453-459.
21. Cañete J.D., Santiago B., Cantaert T., Sanmartí R., Palacin A., Celis R., et al. Ectopic lymphoid neogenesis in psoriatic arthritis. Ann Rheum Dis 2007, 66:720-726.
22. Diani M., Altomare G., Reali E. T cell responses in psoriasis and psoriasi arthritis. Autoimmun Rev 2015, 14:286-292.
23. Bandinelli F., Denaro V., Prignano F., Collaku L., Ciancio G., Matucci-Cerinic M. Ultrasonographic wrist and hand abnormalities in early psoriatic arthritis patients: correlation with clinical, dermatological, serological and genetic indices. Clin Exp Rheumatol 2015, 33:330-335.
24. Dolcino M., Lunardi C., Ottria A., Tinazzi E., Patuzzo G., et al. Crossreactive autoantibodies directed against cutaneous and joint antigens are present in psoriatic arthritis. PLoS One 2014, 9:e115424.
25. Shi J., Knevel R., Suwannalai P., van der Linden M.P., Janssen G.M., van Veelen P.A., et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci U S A 2011, 108:17372-17377.
26. Mydel P., Wang Z., Brisslert M., Hellvard A., Dahlberg L.E., Hazen S.L., et al. Carbamylation-dependent activation of T cells: a novel mechanism in the pathogenesis of autoimmune arthritis. J Immunol 2010, 184:6882-6890.
27. Damoiseaux J., Andrade L.E., Fritzler M.J., Shoenfeld Y. Autoantibodies 2015: from diagnostic biomarkers toward prediction, prognosis and prevention. Autoimmun Rev 2015, 14:555-563. 10.1016/j.autrev.2015.01.017.
28. Shi J., van Veelen P.A., Mahler M., Janssen G.M., Drijfhout J.W., Huizinga T.W., et al. Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies. Autoimmun Rev 2014, 13:225-230.
29. Pinegin B., Vorobjeva N., Pinegin V. Neutrophil extracellular traps and their role in the development of chronic inflammation and autoimmunity. Autoimmun Rev 2015, 14:633-640.
30. Valesini G., Gerardi M.C., Iannuccelli C., Pacucci V.A., Pendolino M., Shoenfeld Y. Citrullination and autoimmunity. Autoimmun Rev 2015, 14:490-497.
31. Schreirer S.M., Hollaus M., Hermann M., Jirovetz L., Exner M., Kapiotis S., et al. Carbamoylated free amino acids in uremia: HOCl generates volatile protein modifying and cytotoxic oxidant species from N-carbamoyl-threonine but not threonine. Biochimie 2012, 94:2441-2447.
32. Jaisson S., Larreta-Garde V., Bellon G., Hornebeck W., Garnotel R., Gillery P. Carbamylation differentially alters type I collagen sensitivity to various collagenases. Matrix Biol 2007, 26:190-196.
33. Brink M., Verheul M.K., Rönnelid J., Berglin E., Holmdahl R., Toes R.E., et al. Anti-carbamylated protein antibodies in the pre-symptomatic phase of rheumatoid arthritis, their relationship with multiple anti-citrulline peptide antibodies and association with radiological damage. Arthritis Res Ther 2015, 17:25.
34. Trouw L.A., Mahler M. Closing the serological gap: promising novel biomarkers for the early diagnosis of rheumatoid arthritis. Autoimmun. Rev. 2012, 12:318-322.
35. Yee A., Webb T., Seaman A., et al. Anti-CarP antibodies as promising marker to measure joint damage and disease activity in patients with rheumatoid arthritis. Immunol. Res. 2015, 61:24-30.
36. Rantapää-Dahlqvist S., de Jong B.A., Berglin E., et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003, 48:2741.
37. Hafström I., Engvall I.L., Rönnelid J., Boonen A., van der Heijde D., Svensson B., et al. Rheumatoid factor and anti-CCP do not predict progressive joint damage in patients with early rheumatoid arthritis treated with prednisolone: a randomised study. BMJ Open 2014, 4:e005246.
38. Whiting P.F., Smidt N., Sterne J.A., Harbord R., Burton A., Burke M., et al. Systematic review: accuracy of anti-citrullinated peptide antibodies for diagnosing rheumatoid arthritis. Ann Intern Med 2010, 152:456-464.
39. Corrao S., Corrao S., Argano C., Calvo L., Pistone G. The challenge of using the rheumatoid arthritis diagnostic criteria in clinical practice. Intern Emerg Med 2015, 10:271-275.
40. van de Stadt LA Shi, Levarht E.W., Huizinga T.W., Toes R.E., Trouw L.A., et al. Anti-carbamylated protein antibodies are present in arthralgia patients and predict the development of rheumatoid arthritis. Arthritis Rheum 2013, 65:911-915.
41. Hissink Muller P.C., Anink J., Shi J., et al. Anticarbamylated protein (anti-CarP) antibodies are present in sera of juvenile idiopathic arthritis (JIA) patients. Ann Rheum Dis 2013, 72:2053-2055.
42. Sokolowska M., Niedzielska E., Iciek M., Bilska A., Lorenc-Koci E., Wlodek L. The effect of the uremic toxin cyanate (CNO-) on anaerobic cysteine metabolism and oxidative processes in the rat liver: a protective effect of lipoate. Toxicol Mech Methods 2011, 21:473-478.